Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
From MaRDI portal
Publication:4696421
DOI10.2307/2532350zbMath0825.62842WikidataQ45253654 ScholiaQ45253654MaRDI QIDQ4696421
Publication date: 29 June 1993
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2532350
62P10: Applications of statistics to biology and medical sciences; meta analysis
Related Items
A new design of the continual reassessment method, A system for determining maximum tolerated dose in clinical trial, Continual reassessment and related dose-finding designs, Adaptive clinical trial designs for phase I cancer studies, Theoretical study of the continual reassessment method, Dose-Finding Designs for HIV Studies